Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlumasc Group Regulatory News (ALU)

Share Price Information for Alumasc Group (ALU)

Share Price is delayed by 15 minutes
Get Live Data
240.00    5.00 (2.13%)
Bid:
235.00
Ask:
245.00
Spread: 10.00 (4.255%)
Market Cap: £86.30m
ALU Live PriceLast checked at - London Stock Exchange

Intraday Alumasc Group Share Chart

Trading Statement

19 Jan 2021 07:00

RNS Number : 0821M
Alumasc Group PLC
19 January 2021
 

19 January 2021

THE ALUMASC GROUP PLC

("ALUMASC")

TRADING UPDATE FOR SIX MONTHS ENDED 31 DECEMBER 2020

 

Alumasc, the premium building products, systems, and solutions Group, today provides a trading update for the six months ended 31 December 2020, ahead of publication of its half-year results on Thursday 4 February 2021.

Our absolute focus continues to be the safety of our employees, customers, suppliers, and sub-contractors as we continue to manage with the Covid-19 pandemic and the latest lockdown guidelines.

Record Half Year Performance

Further to our AGM Trading Update on 22 October 2020, which reported a strong performance in the first quarter, we are very pleased to report that conditions in our markets have remained positive and that the Group's trading performance has continued through to the end of the first half of the financial year, with a record profit for the period being achieved. On an unaudited basis, for the first six months of the year:

· Revenue increased 11% versus the prior year to £45.6m

· Underlying PBT increased significantly, from £2.3m to £6.0m

· Cash generation has also been strong in the first half, with net bank debt reducing from £4.3m at 30 June 2020 to £0.2m at 31 December 2020.

 

Pleasingly, all our divisions have contributed to the strong performance. While trading in the period includes an element of catch-up demand following the UK's first national lockdown and has benefitted from a range of Government support for the construction industry, our businesses have also been successful in winning market share and have been further supported by encouraging export sales. Additionally, the restructuring during FY2020, which provided £2.4 million in annual cost savings, benefitted margins. Levolux also continues to respond well to the business's turnaround plan, achieving a profit in each month of the first half of this financial year.

Outlook

The business has entered H2 with good momentum, a healthy forward sales position, and a well-capitalised balance sheet, creating the potential to deliver a strong result for the year. Nevertheless, we remain mindful of the continued economic uncertainties, particularly the risk of disruption to our business and markets in the near term as a result of the on-going pandemic and the establishment of efficient cross-border goods movement following the entry into the Free Trade Agreement with the EU. Conditions in our markets, particularly in the new build housing and RMI sectors, have been very supportive coming into the second half and we would anticipate demand remaining good through the coming months. We are also continuing to monitor the potential impact of changes to UK Government incentives within the housebuilding industry, notably around the current Help to Buy Scheme being extended beyond 28 February 2021 and Stamp Duty and changes here may affect our final quarter, albeit the potential impact is difficult to predict. However, we are encouraged by the UK's accelerating rollout of vaccines and mass testing, which should provide some counterbalance in our markets. Overall, this has been a most encouraging performance by Alumasc in the first half and there is an excellent platform to deliver sustainable shareholder value.

Paul Hooper, CEO, commented, "It is very encouraging to see Alumasc's achievement of a double digit growth in revenues and also a double digit return on sales and H1 has absolutely shown the great potential for the Group. In light of the businesses' momentum and strong cash conversion, a resumption of Alumasc's previous dividend policy is being considered by the Board."

This announcement contains inside information.

Enquiries:

Paul Hooper, CEO

Helen Ashton, Group Company Secretary

+ 44 (0) 1536 383844

+ 44 (0) 1536 383812

 

Peel Hunt (Broker)

Mike Bell + 44 (0)207 418 8831

 

finnCap (NOMAD)

Julian Blunt + 44 (0)207 220 0561

Camarco:

Ginny Pulbrook + 44 (0)203 757 4992

Tom Huddart + 44 (0)203 757 4991

Email: alumasc@camarco.co.uk

 

 

Notes to Editors:

Alumasc is a UK-based supplier of premium building products, systems and solutions. Almost 80% of group sales are driven by building regulations and specifications (architects and structural engineers) because of the performance characteristics offered.

 

The Group has three business segments with strong positions and brands in their individual markets. The three segments are: Water Management; Building Envelope; and Housebuilding Products.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFSRLFITLIL
Date   Source Headline
6th May 20261:21 pmRNSHolding(s) in Company
21st Apr 20267:00 amRNSDirector Dealings
20th Apr 20262:37 pmRNSHolding(s) in Company
16th Apr 20267:00 amRNSQ3 Trading Update
1st Apr 20267:00 amRNSConfirmation of CEO appointment
9th Feb 20267:00 amRNS-RMelloMonday Investor Webinar
3rd Feb 20267:00 amRNSInterim Results
15th Jan 20267:00 amRNSDirectorate change
10th Dec 20259:36 amRNSNotice of Half Year Results
21st Nov 20252:17 pmRNSDirector/PDMR Shareholding
7th Nov 202511:22 amRNSDirector/PDMR Shareholding
5th Nov 20252:50 pmRNSDirector/PDMR Shareholding
4th Nov 202511:03 amRNSDirector/PDMR Shareholding
24th Oct 20251:52 pmRNSResult of AGM
24th Oct 20257:00 amRNSAGM Trading Update
23rd Sep 20257:00 amRNSCEO Retirement & 2025 AGM Notice & Annual Accounts
2nd Sep 20257:00 amRNSFinal Results - Unaudited
21st Jul 20257:00 amRNSNotice of FY Results and Investor Presentation
15th Jul 20257:00 amRNSFull Year Trading Update
11th Jun 20253:46 pmRNSDirector/PDMR Shareholding
27th May 20257:00 amRNSAppointment of Non-executive Director
4th Apr 20257:00 amRNS-ROpening new Wade/Gatic building extension
21st Mar 20257:00 amRNSAppointment of Joint Broker
12th Mar 202511:15 amRNSDirector/PDMR Shareholding
4th Feb 20257:00 amRNSHalf-year Results
27th Nov 202412:22 pmRNSNotice of Half Year Results
6th Nov 20241:40 pmRNSDirector/PDMR Shareholding
5th Nov 20248:00 amRNSDirector/PDMR Shareholding
1st Nov 202411:15 amRNSDirector/PDMR Shareholding
29th Oct 20247:00 amRNSDirector/PDMR Shareholding
24th Oct 20241:38 pmRNSResult of AGM
24th Oct 20247:00 amRNSAGM Trading Update
23rd Oct 202412:53 pmRNSDirector/PDMR Shareholding
10th Oct 20247:00 amRNSNotice of Capital Markets Event
4th Oct 20247:00 amRNSDirectorate Change
20th Sep 20242:15 pmRNSNotice of AGM
18th Sep 20242:32 pmRNSDirector/PDMR Shareholding
3rd Sep 20247:00 amRNSFinal Results
25th Jul 20248:00 amRNSNotice of Results
18th Jul 20247:00 amRNSFull Year Trading Update
25th Apr 20249:38 amRNSHolding(s) in Company
27th Feb 202412:31 pmRNSDirector/PDMR Shareholding
14th Feb 20241:01 pmRNSDirector/PDMR Shareholding
6th Feb 20247:00 amRNSInterim results
11th Jan 20247:00 amRNSNotice of Interim Results
3rd Jan 202412:52 pmRNSDirector/PDMR Shareholding
19th Dec 20239:50 amRNSDirector/PDMR Shareholding
18th Dec 20233:17 pmRNSDirector/PDMR Shareholding
18th Dec 20231:23 pmRNSDirector/PDMR Shareholding
18th Dec 20231:10 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.